Jessica Casas1, David F Friedman1,2, Tannoa Jackson1, Sunitha Vege3, Connie M Westhoff3, Stella T Chou1. 1. Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 2. Department of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 3. Immunohematology and Genomics Laboratory, New York Blood Center, New York City, New York.
Abstract
BACKGROUND: Extended red blood cell (RBC) antigen matching is recommended to limit alloimmunization in patients with sickle cell disease (SCD). DNA-based testing to predict blood group phenotypes has enhanced availability of antigen-negative donor units and improved typing of transfused patients, but replacement of routine serologic typing for non-ABO antigens with molecular typing for patients has not been reported. STUDY DESIGNS AND METHODS: This study compared the historical RBC antigen phenotypes obtained by hemagglutination methods with genotype predictions in 494 patients with SCD. For discrepant results, repeat serologic testing was performed and/or investigated by gene sequencing for silent or variant alleles. RESULTS: Seventy-one typing discrepancies were identified among 6360 antigen comparisons (1.1%). New specimens for repeat serologic testing were obtained for 66 discrepancies and retyping agreed with the genotype in 64 cases. One repeat Jk(b-) serologic phenotype, predicted Jk(b+) by genotype, was found by direct sequencing of JK to be a silenced allele, and one N typing discrepancy remains under investigation. Fifteen false-negative serologic results were associated with alleles encoding weak antigens or single-dose Fy(b) expression. CONCLUSIONS: DNA-based RBC typing provided improved accuracy and expanded information on RBC antigens compared to hemagglutination methods, leading to its implementation as the primary method for extended RBC typing for patients with SCD at our institution.
BACKGROUND: Extended red blood cell (RBC) antigen matching is recommended to limit alloimmunization in patients with sickle cell disease (SCD). DNA-based testing to predict blood group phenotypes has enhanced availability of antigen-negative donor units and improved typing of transfused patients, but replacement of routine serologic typing for non-ABO antigens with molecular typing for patients has not been reported. STUDY DESIGNS AND METHODS: This study compared the historical RBC antigen phenotypes obtained by hemagglutination methods with genotype predictions in 494 patients with SCD. For discrepant results, repeat serologic testing was performed and/or investigated by gene sequencing for silent or variant alleles. RESULTS: Seventy-one typing discrepancies were identified among 6360 antigen comparisons (1.1%). New specimens for repeat serologic testing were obtained for 66 discrepancies and retyping agreed with the genotype in 64 cases. One repeat Jk(b-) serologic phenotype, predicted Jk(b+) by genotype, was found by direct sequencing of JK to be a silenced allele, and one N typing discrepancy remains under investigation. Fifteen false-negative serologic results were associated with alleles encoding weak antigens or single-dose Fy(b) expression. CONCLUSIONS: DNA-based RBC typing provided improved accuracy and expanded information on RBC antigens compared to hemagglutination methods, leading to its implementation as the primary method for extended RBC typing for patients with SCD at our institution.
Authors: C Tournamille; C Le Van Kim; P Gane; P Y Le Pennec; F Roubinet; J Babinet; J P Cartron; Y Colin Journal: Blood Date: 1998-09-15 Impact factor: 22.113
Authors: Chibuzo O'Suoji; Robert I Liem; A Kyle Mack; Paris Kingsberry; Glenn Ramsey; Alexis A Thompson Journal: Pediatr Blood Cancer Date: 2013-03-18 Impact factor: 3.167
Authors: Scott T Miller; Hae-Young Kim; Debra L Weiner; Carrie G Wager; Dianne Gallagher; Lori A Styles; Carlton D Dampier; Susan D Roseff Journal: Transfusion Date: 2012-07-13 Impact factor: 3.157
Authors: Neil D Avent; Antonio Martinez; Willy A Flegel; Martin L Olsson; Marion L Scott; Núria Nogués; Martin Písăcka; Geoff L Daniels; Eduardo Muñiz-Diaz; Tracey E Madgett; Jill R Storry; Sigrid Beiboer; Petra M Maaskant-van Wijk; Inge von Zabern; Elisa Jiménez; Diego Tejedor; Monica López; Emma Camacho; Goedele Cheroutre; Anita Hacker; Pavel Jinoch; Irena Svobodova; Ellen van der Schoot; Masja de Haas Journal: Transfus Med Hemother Date: 2009-05-28 Impact factor: 3.747
Authors: Pablo Cure; Melania Bembea; Stella Chou; Allan Doctor; Anne Eder; Jeanne Hendrickson; Cassandra D Josephson; Alan E Mast; William Savage; Martha Sola-Visner; Philip Spinella; Simon Stanworth; Marie Steiner; Traci Mondoro; Shimian Zou; Catherine Levy; Myron Waclawiw; Nahed El Kassar; Simone Glynn; Naomi L C Luban Journal: Transfusion Date: 2017-03-28 Impact factor: 3.157
Authors: Carla L Dinardo; Shannon Kelly; Marcia R Dezan; Ingrid H Ribeiro; Shirley L Castilho; Luciana C Schimidt; Maria do C Valgueiro; Liliana R Preiss; Brian Custer; Ester C Sabino; Connie M Westhoff Journal: Transfusion Date: 2019-08-13 Impact factor: 3.157
Authors: Jan Portegys; Gabi Rink; Pia Bloos; Erwin A Scharberg; Harald Klüter; Peter Bugert Journal: Transfus Med Hemother Date: 2018-09-24 Impact factor: 3.747